Preliminary testing of a patient decision aid for patients with relapsing-remitting multiple sclerosis.
Multiple sclerosis
decision aid
decision-making
disease-modifying therapies
relapsing-remitting
treatment
Journal
Multiple sclerosis journal - experimental, translational and clinical
ISSN: 2055-2173
Titre abrégé: Mult Scler J Exp Transl Clin
Pays: United States
ID NLM: 101668877
Informations de publication
Date de publication:
Historique:
received:
22
01
2021
accepted:
15
06
2021
entrez:
5
8
2021
pubmed:
6
8
2021
medline:
6
8
2021
Statut:
epublish
Résumé
Multiple first-line disease modifying therapies (DMTs) are available for relapsing-remitting multiple sclerosis (RRMS), each with different characteristics. We developed an interactive patient decision aid (PtDA) to promote informed shared decision-making (SDM). To test the preliminary effectiveness of the PtDA in participants with RRMS. Knowledge, and decisional conflict were measured pre- and post- implementation of the PtDA, SDM after the consultation, and 6-month treatment patterns were observed. Differences in scores were analyzed using descriptive statistics and paired t-tests. Qualitative interviews with patients and neurologists were analyzed using thematic analysis. 52 participants were recruited: most were female (81%), 40 years of age or younger (62%), and had experienced MS for less than 5 years (56%). After participants used the PtDA, there was a significant improvement in decisional conflict (change = 1.00; This pilot study suggests that PtDA use helps RRMS patients and their clinician select a DMT. Future studies will assess the feasibility of implementation and the impact of the PtDA on timely DMT initiation and longer-term adherence.
Sections du résumé
BACKGROUND
BACKGROUND
Multiple first-line disease modifying therapies (DMTs) are available for relapsing-remitting multiple sclerosis (RRMS), each with different characteristics. We developed an interactive patient decision aid (PtDA) to promote informed shared decision-making (SDM).
OBJECTIVE
OBJECTIVE
To test the preliminary effectiveness of the PtDA in participants with RRMS.
METHODS
METHODS
Knowledge, and decisional conflict were measured pre- and post- implementation of the PtDA, SDM after the consultation, and 6-month treatment patterns were observed. Differences in scores were analyzed using descriptive statistics and paired t-tests. Qualitative interviews with patients and neurologists were analyzed using thematic analysis.
RESULTS
RESULTS
52 participants were recruited: most were female (81%), 40 years of age or younger (62%), and had experienced MS for less than 5 years (56%). After participants used the PtDA, there was a significant improvement in decisional conflict (change = 1.00;
CONCLUSION
CONCLUSIONS
This pilot study suggests that PtDA use helps RRMS patients and their clinician select a DMT. Future studies will assess the feasibility of implementation and the impact of the PtDA on timely DMT initiation and longer-term adherence.
Identifiants
pubmed: 34350027
doi: 10.1177/20552173211029966
pii: 10.1177_20552173211029966
pmc: PMC8287362
doi:
Types de publication
Journal Article
Langues
eng
Pagination
20552173211029966Informations de copyright
© The Author(s) 2021.
Références
Can J Nurs Res. 1997 Fall;29(3):21-43
pubmed: 9505581
J Med Econ. 2016;19(1):21-33
pubmed: 26360615
CMAJ. 2007 May 22;176(11):1597-8
pubmed: 17515586
J Clin Epidemiol. 2016 Sep;77:15-23
pubmed: 27185074
Cochrane Database Syst Rev. 2014 Jan 28;(1):CD001431
pubmed: 24470076
Neurology. 1995 Feb;45(2):251-5
pubmed: 7854521
Medscape J Med. 2008;10(9):225
pubmed: 19008986
Ther Adv Neurol Disord. 2011 Jan;4(1):3-14
pubmed: 21339904
J Neurol Sci. 2008 Dec 15;275(1-2):86-91
pubmed: 18786682
Can J Neurol Sci. 2013 May;40(3):307-23
pubmed: 23603165
Neuroepidemiology. 2013;40(3):195-210
pubmed: 23363936
BMC Neurol. 2019 Jul 20;19(1):173
pubmed: 31325961
BMJ. 2012 Nov 08;345:e6572
pubmed: 23137819
Med Decis Making. 2020 Dec 15;:272989X20978208
pubmed: 33319621
Autoimmun Rev. 2014 Apr-May;13(4-5):518-24
pubmed: 24424194
Med Decis Making. 2013 Jan;33(1):78-84
pubmed: 22927695
Mult Scler. 2004 Dec;10(6):643-50
pubmed: 15584489
Appl Health Econ Health Policy. 2013 Jun;11(3):163-80
pubmed: 23529716
Mult Scler Relat Disord. 2016 Sep;9 Suppl 1:S5-S48
pubmed: 27640924
Expert Rev Neurother. 2012 Mar;12(3):343-52
pubmed: 22364333
Health Educ Res. 2009 Oct;24(5):788-98
pubmed: 19304927
Ther Adv Neurol Disord. 2016 Jul;9(4):287-96
pubmed: 27366235
J Manag Care Pharm. 2013 Jan-Feb;19(1 Suppl A):S24-40
pubmed: 23383731
Int J MS Care. 2018 Nov-Dec;20(6):287-297
pubmed: 30568566
Mult Scler. 2005 Oct;11(5):516-9
pubmed: 16193887
PLoS One. 2015 Jul 27;10(7):e0133279
pubmed: 26214805
Mayo Clin Proc. 2014 Feb;89(2):225-40
pubmed: 24485135
Med Decis Making. 2011 Jan-Feb;31(1):121-9
pubmed: 20519453
Can Fam Physician. 2010 Aug;56(8):e308-14
pubmed: 20705870
BMJ Open. 2017 May 17;7(5):e014719
pubmed: 28515194